ArticleDiagnostic pathology2026
Histological features of liver biopsy in patients with COVID-19: a single institution experience with long term follow-up outcome.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 is caused by SARS-CoV2, which primarily produces respiratory disease. Although liver enzyme abnormalities are common in patients with COVID-19, little is known about histological changes in the liver. Most of the available information is based on autopsy studies, with limited liver biopsy studies in living patients.
methodsLiver biopsies performed between March 2021 and September 2021 in patients with a history of COVID-19 were retrieved, and 17 biopsies were reviewed. Additionally, immunohistochemical staining for the SARS-CoV2 nucleocapsid protein was performed in all cases. The clinical follow-up period was 36 months.
resultsAfter reviewing the clinical data, the biopsies were grouped into three cohorts: (1) those with no underlying liver disease, (2) those with preexisting liver disease, and (3) those with liver post-transplant allografts. In patients without underlying liver disease, there were small clusters of debris-laden macrophages in the portal areas and lobules, as highlighted by periodic acid-Schiff and diastase staining. Increased mitosis and binucleated hepatocytes were common, and rare micro-abscesses were also observed. These findings indicated mild non-specific hepatitis, and no severe inflammatory infiltrates were observed in portal areas or lobules. These features are highly suggestive of hepatitis resolution. Patients with previous liver disease showed microscopic features compatible with underlying liver disease, without any additional features that could be attributed to COVID-19. Posttransplant allograft biopsies showed no special features that could be described as occurring solely due to COVID-19. All patients tested negative on SARS-CoV2 nucleoprotein immunostains.
conclusionsLiver biopsies performed after COVID-19 demonstrated a mildly resolved hepatitis-like pattern. 36 months after biopsy, all patients in Group 1 and all surviving patients in Group 2 and 3 presented normal liver enzyme levels. It is therefore, from this small case series, that the liver may not be the target of significant inflammatory damage in COVID-19 and that liver injuries are resolved over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.